Sun Pharmaceutical Industries has promoted Aalok Shanghvi, son of founder-promoter Dilip Shanghvi, to the position of Chief Operating Officer (COO).
Aalok will continue to serve as a whole-time director while overseeing emerging markets, global generic R&D, global business development (Generics), operations, and active pharmaceutical ingredients (API).
Extensive Experience Within Sun Pharma
Aalok began his journey with Sun Pharmaceutical Industries in 2006, taking on key roles across various functions, including marketing, research and development, project management, purchase, and communications.
His experience across multiple domains has played a crucial role in the company’s growth and expansion.
Driving Growth in Emerging Markets
In 2014, Aalok assumed leadership of Sun Pharma’s Emerging Markets division, managing operations across 80 countries, including Africa, the Middle East, APAC, Eastern Europe, CIS, and LATAM.
Under his leadership, the emerging markets business has grown significantly, now contributing approximately 18% to the company’s global revenues.
Expanding Responsibilities
Over the years, Aalok took on additional responsibilities, leading Sun Pharma’s global generic R&D, global business development (generics), operations, and API functions.
His contributions have been instrumental in strengthening the company’s global presence.
As reported by thehindubusinessline.com, Sun Pharma has decided to elevate Aalok Shanghvi. This move reflects the company’s commitment to strong leadership and strategic growth in the global pharmaceutical industry.
